The companies announced last July that they plan to combine Mylan with Upjohn to create a global pharmaceutical giant producing both generic and brand-name drugs. The drugmakers said last November they plan to call the combined company Viatris.
Due to delays in the regulatory review process caused by the COVID-19 pandemic, Mylan said it’s pushing back the meeting for shareholders to approve the deal from April 27 to June 30.
The drugmaker said the companies aren’t changing any terms of the deal.
Read the full news release here.
More articles on pharmacy:
Gilead asks FDA to take back orphan drug status for COVID-19 drug
Walmart nearly criminally charged over opioid prescriptions, report finds
13 drugmakers form consortium to find COVID-19 treatments
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.